利用Panbio COVID-19抗原快速检测装置剩余样本进行关注的SARS-CoV-2变异的分子筛选B.1.1.7

M. Montes, J. Marimón, L. Piñeiro, Tania Martín-Peñaranda, Marta Gomez-Ruiz de Arbulo, G. Cilla, M. Montes, J. Marimón, L. Piñeiro, G. Cilla
{"title":"利用Panbio COVID-19抗原快速检测装置剩余样本进行关注的SARS-CoV-2变异的分子筛选B.1.1.7","authors":"M. Montes, J. Marimón, L. Piñeiro, Tania Martín-Peñaranda, Marta Gomez-Ruiz de Arbulo, G. Cilla, M. Montes, J. Marimón, L. Piñeiro, G. Cilla","doi":"10.14302/issn.2690-4721.ijcm-21-3835","DOIUrl":null,"url":null,"abstract":"Objective\nReal-time surveillance of SARS-CoV-2 variants of concern (VOC) is of essential public health importance. Rapid Antigen Detection Tests (RAgDT) have become first-line COVID-19 diagnostic methods in many regions, but this strategy can hamper the surveillance of the virus variants due to their decentralized performance. The aim of this study was to assess the usefulness of the remaining sample of a widely used RAgDT (Panbio) for the surveillance of the B.1.1.7 VOC using molecular methods.\n\nMethods\nSymptomatic individuals and asymptomatic close contacts of confirmed cases were routinely screened for SARS-CoV-2 infection using the RAgDT in Primary Health Care Centers. After performing the test, the extraction tubes containing the remaining biological material of RAgDT-positive cases were sent to the clinical microbiology laboratory where RT-PCRs detecting key mutations of the VOC were conducted.\n\nResults\nA valid result was obtained in 1770/1812 (97.7%) RAgDT-positive cases. Variant B.1.1.7 was detected in 34.7% of the patients, increasing from 0% to 87.7% between the weeks beginning January 4 and March 15, 2021.\n\nConclusion\nThe sample remaining after performing the Panbio RAgDT allowed to monitor the emergence and circulation of the B.1.1.7, greatly improving the population screened for the molecular study of SARS-CoV-2 variants.","PeriodicalId":228152,"journal":{"name":"International Journal of Clinical Microbiology","volume":"74 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of the Remaining Sample from the Panbio COVID-19 Antigen Rapid Test Device for the Molecular Screening of the SARS-CoV-2 Variant of Concern B.1.1.7\",\"authors\":\"M. Montes, J. Marimón, L. Piñeiro, Tania Martín-Peñaranda, Marta Gomez-Ruiz de Arbulo, G. Cilla, M. Montes, J. Marimón, L. Piñeiro, G. Cilla\",\"doi\":\"10.14302/issn.2690-4721.ijcm-21-3835\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective\\nReal-time surveillance of SARS-CoV-2 variants of concern (VOC) is of essential public health importance. Rapid Antigen Detection Tests (RAgDT) have become first-line COVID-19 diagnostic methods in many regions, but this strategy can hamper the surveillance of the virus variants due to their decentralized performance. The aim of this study was to assess the usefulness of the remaining sample of a widely used RAgDT (Panbio) for the surveillance of the B.1.1.7 VOC using molecular methods.\\n\\nMethods\\nSymptomatic individuals and asymptomatic close contacts of confirmed cases were routinely screened for SARS-CoV-2 infection using the RAgDT in Primary Health Care Centers. After performing the test, the extraction tubes containing the remaining biological material of RAgDT-positive cases were sent to the clinical microbiology laboratory where RT-PCRs detecting key mutations of the VOC were conducted.\\n\\nResults\\nA valid result was obtained in 1770/1812 (97.7%) RAgDT-positive cases. Variant B.1.1.7 was detected in 34.7% of the patients, increasing from 0% to 87.7% between the weeks beginning January 4 and March 15, 2021.\\n\\nConclusion\\nThe sample remaining after performing the Panbio RAgDT allowed to monitor the emergence and circulation of the B.1.1.7, greatly improving the population screened for the molecular study of SARS-CoV-2 variants.\",\"PeriodicalId\":228152,\"journal\":{\"name\":\"International Journal of Clinical Microbiology\",\"volume\":\"74 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Microbiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14302/issn.2690-4721.ijcm-21-3835\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14302/issn.2690-4721.ijcm-21-3835","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的实时监测SARS-CoV-2关注变异体(VOC)具有重要的公共卫生意义。快速抗原检测(RAgDT)已成为许多地区COVID-19的一线诊断方法,但由于其分散的性能,这种策略可能会阻碍对病毒变体的监测。本研究的目的是评估广泛使用的RAgDT (Panbio)剩余样品使用分子方法监测B.1.1.7 VOC的有效性。方法对确诊病例有症状的个体和无症状的密切接触者采用RAgDT法进行常规筛查。检测完成后,将含有ragdt阳性病例剩余生物材料的提取管送至临床微生物实验室,进行rt - pcr检测VOC关键突变。结果ragdt阳性病例1770/1812例(97.7%)获得有效结果。变异B.1.1.7在34.7%的患者中检测到,在2021年1月4日至3月15日的几周内从0%增加到87.7%。结论Panbio RAgDT后的剩余样本可以监测B.1.1.7的出现和传播,大大提高了对SARS-CoV-2变异体分子研究的筛查人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Use of the Remaining Sample from the Panbio COVID-19 Antigen Rapid Test Device for the Molecular Screening of the SARS-CoV-2 Variant of Concern B.1.1.7
Objective Real-time surveillance of SARS-CoV-2 variants of concern (VOC) is of essential public health importance. Rapid Antigen Detection Tests (RAgDT) have become first-line COVID-19 diagnostic methods in many regions, but this strategy can hamper the surveillance of the virus variants due to their decentralized performance. The aim of this study was to assess the usefulness of the remaining sample of a widely used RAgDT (Panbio) for the surveillance of the B.1.1.7 VOC using molecular methods. Methods Symptomatic individuals and asymptomatic close contacts of confirmed cases were routinely screened for SARS-CoV-2 infection using the RAgDT in Primary Health Care Centers. After performing the test, the extraction tubes containing the remaining biological material of RAgDT-positive cases were sent to the clinical microbiology laboratory where RT-PCRs detecting key mutations of the VOC were conducted. Results A valid result was obtained in 1770/1812 (97.7%) RAgDT-positive cases. Variant B.1.1.7 was detected in 34.7% of the patients, increasing from 0% to 87.7% between the weeks beginning January 4 and March 15, 2021. Conclusion The sample remaining after performing the Panbio RAgDT allowed to monitor the emergence and circulation of the B.1.1.7, greatly improving the population screened for the molecular study of SARS-CoV-2 variants.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信